EUVIMEDDescoperă EUVIMED
Open access · CC BY-NC-ND 4.0

Towards a scalable bioprocess for rAAV production using a HeLa stable cell line

José Escandell iD, Filipa Moura, Sofia B Carvalho, Ricardo J S Silva iD, Ricardo Correia, Antonio Roldão, Patrícia Gomes-Alves iD, Paula M Alves

Biotechnology and Bioengineering · 2023

DOI: 10.1002/bit.28394 ↗

At a glance

Journal article in Biotechnology and Bioengineering, 2023. Written by José Escandell and 7 co-authors. Institution: iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal. Major MEDLINE topics: Dependovirus, Genetic Vectors. Cited 16 times so far (Crossref); 19 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Horizon 2020 Framework Programme, Fundação para a Ciência e a Tecnologia.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

The majority of recombinant adeno‐associated viruses (rAAV) approved for clinical use or in clinical trials areproduced by transient transfection using the HEK293 cell line. However, this platform has several manufacturing bottlenecks at commercial scales namely, low product quality (full to empty capsid ratio 3 × 10 11 vg/mL and full to empty capsids ratio (>70%) at 2 L bioreactor scale. Moreover, the established downstream process, based on ion exchange and affinity‐based chromatography, efficiently eliminated process related impurities, including the Adenovirus 5 helper virus required for production with a log reduction value of 9. Overall, we developed a time‐efficient and robust rAAV bioprocess using a stable producer cell line achieving purified rAAV2 yields > 1 × 10 11 vg/mL. This optimized platform may address manufacturing challenges for rAAV based medicines.

Subjects

MeSH terms (MEDLINE)

DependovirusGenetic VectorsHumansHEK293 CellsHeLa CellsTransfection

Author keywords

HeLaS3bioprocess developmentcell line developmentdownstream processinggene therapyrecombinant adeno-associated viruses (rAAV)stable cell line

Authors and institutions

  • iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
  • ITQB-NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.

ORCID profiles: José Escandell, Ricardo J S Silva, Patrícia Gomes-Alves

Funding

  • Horizon 2020 Framework Programme
  • Fundação para a Ciência e a Tecnologia

Cite

APA

Escandell, J., Moura, F., Carvalho, S. B., Silva, R. J. S., Correia, R., Roldão, A., Gomes-Alves, P., & Alves, P. M. (2023). Towards a scalable bioprocess for rAAV production using a HeLa stable cell line. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28394

Vancouver

Escandell J, Moura F, Carvalho SB, Silva RJS, Correia R, Roldão A, et al. Towards a scalable bioprocess for rAAV production using a HeLa stable cell line. Biotechnology and Bioengineering. 2023. doi:10.1002/bit.28394

BibTeX
@article{Escandell2023,
  author = {Escandell, José and Moura, Filipa and Carvalho, Sofia B and Silva, Ricardo J S and Correia, Ricardo and Roldão, Antonio and Gomes-Alves, Patrícia and Alves, Paula M},
  title = {Towards a scalable bioprocess for rAAV production using a HeLa stable cell line},
  journal = {Biotechnology and Bioengineering},
  year = {2023},
  doi = {10.1002/bit.28394}
}
Start for free →